# Thomas Goebel

> Thomas Goebel is a Series A investor at Neomed Management backing Biotechnology and Medical Device. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Neomed Management](https://shizune.co/investors/profile/neomed-management)
- Total investments: 2
- Last investment: Jun 2013
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/thomas-goebel/1/a68/607

Thomas Goebel is a Series A investor at Neomed Management focused on Biotechnology and Medical Device. Thomas Goebel joined NeoMed Management in 2005 as a Senior Associate and became a Principal in 2008. He has over 10 years of experience of venture capital investing in healthcare in Europe.Previously Thomas was a global biotechnology analyst for Pictet & Cie, Switzerland's largest private bank. He was also Manager of Regulatory Affairswith worldwide responsibilities at Firmenich SA, a global leader in fragrances, flavourings and fine chemicals.Thomas has been a board member of Sequana Medical AG, and a board observer of Novexel SA and currently serves on the board of directors of Diagnoplex SA and Kuros Biosurgery AG. Thomas holds a Ph.D. in molecular biology form the University of Geneva, Switzerland.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Diagnoplex | Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity. | $1.5M |  | Jun 07, 2013 |  |
| Diagnoplex | Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity. | $8.3M | Series A | Dec 13, 2008 |  |

2 of 2 investments shown.

## Co-investors
- [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund) — VC Fund, 1 deal together
- [Initiative Capital Romandie](https://shizune.co/investors/profile/initiative-capital-romandie) — VC Fund, 1 deal together

## About Neomed Management

VC Fund · Oslo, Norway

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

5 contacts available at Neomed Management.

| Name | Title | Profile |
| --- | --- | --- |
| Erik Amble | Founder, Chairman & Managing Partner | https://shizune.co/investors/profile/erik-amble-8d03 |
| Thomas Goebel | Principal | https://shizune.co/investors/profile/thomas-goebel |
| Vincent Ossipow | Partner | https://shizune.co/investors/profile/vincent-ossipow |
| Claudio Nessi | Partner | https://shizune.co/investors/profile/claudio-nessi |
| Line B. Westlund | Office Manager | https://shizune.co/investors/profile/line-b-westlund |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Thomas Goebel invest in?

Thomas Goebel invests primarily in Biotechnology and Medical Device startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Thomas Goebel last invest?

The most recent investment recorded for Thomas Goebel closed in Jun 2013. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co